Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Nanoscale ; 6(22): 13770-8, 2014 Nov 21.
Artículo en Inglés | MEDLINE | ID: mdl-25285425

RESUMEN

Acute respiratory infections represent a significant portion of global morbidity and mortality annually. There is a critical need for efficacious vaccines against respiratory pathogens. To vaccinate against respiratory disease, pulmonary delivery is an attractive route because it mimics the route of natural infection and can confer both mucosal and systemic immunity. We have previously demonstrated that a single dose, intranasal vaccine based on polyanhydride nanoparticles elicited a protective immune response against Yersinia pestis for at least 40 weeks after immunization with F1-V. Herein, we investigate the effect of nanoparticle chemistry and its attributes on the kinetics and maturation of the antigen-specific serum antibody response. We demonstrate that manipulation of polyanhydride nanoparticle chemistry facilitated differential kinetics of development of antibody titers, avidity, and epitope specificity. The results provide new insights into the underlying role(s) of nanoparticle chemistry in providing long-lived humoral immunity and aid in the rational design of nanovaccine formulations to induce long-lasting and mature antibody responses.


Asunto(s)
Formación de Anticuerpos/efectos de los fármacos , Inmunidad Humoral/efectos de los fármacos , Vacuna contra la Peste/administración & dosificación , Vacuna contra la Peste/química , Nanomedicina Teranóstica , Yersinia pestis/inmunología , Administración Intranasal , Animales , Disponibilidad Biológica , Inmunización/métodos , Pulmón/efectos de los fármacos , Pulmón/inmunología , Pulmón/metabolismo , Ratones , Ratones Endogámicos C57BL , Peste/metabolismo , Peste/prevención & control , Vacuna contra la Peste/síntesis química , Vacuna contra la Peste/farmacocinética , Polianhídridos/síntesis química , Polianhídridos/química , Polianhídridos/farmacocinética
2.
Comp Immunol Microbiol Infect Dis ; 36(2): 113-28, 2013 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-23195858

RESUMEN

Yersinia pestis causes bubonic and pneumonic plague in humans. The pneumonic infection is the most severe and invariably fatal if untreated. Because of its high virulence, ease of delivery and precedent of use in warfare, Y. pestis is considered as a potential bioterror agent. No licensed plague vaccine is currently available in the US. Laboratory research with virulent strains requires appropriate biocontainment (i.e., Biosafety Level 3 (BSL-3) for procedures that generate aerosol/droplets) and secure facilities that comply with federal select agent regulations. To assist in the identification of promising vaccine candidates during the early phases of development, we characterized mouse models of systemic and pneumonic plague infection using the Y. pestis strain EV76, an attenuated human vaccine strain that can be rendered virulent in mice under in vivo iron supplementation. Mice inoculated intranasally or intravenously with Y. pestis EV76 in the presence of iron developed a systemic and pneumonic plague infection that resulted in disease and lethality. Bacteria replicated and severely compromised the spleen, liver and lungs. Susceptibility was age dependent, with younger mice being more vulnerable to pneumonic infection. We used these models of infection to assess the protective capacity of newly developed Salmonella-based plague vaccines. The protective outcome varied depending on the route and dose of infection. Protection was associated with the induction of specific immunological effectors in systemic/mucosal compartments. The models of infection described could serve as safe and practical tools for identifying promising vaccine candidates that warrant further potency evaluation using fully virulent strains in BSL-3 settings.


Asunto(s)
Peste/prevención & control , Yersinia pestis/inmunología , Administración Intranasal , Administración Intravenosa , Animales , Anticuerpos Antibacterianos/sangre , Anticuerpos Antibacterianos/inmunología , Antígenos Bacterianos/genética , Antígenos Bacterianos/inmunología , Modelos Animales de Enfermedad , Susceptibilidad a Enfermedades , Femenino , Inmunoglobulina A Secretora , Inmunoglobulina G/sangre , Inmunoglobulina G/inmunología , Dosificación Letal Mediana , Ratones , Peste/mortalidad , Peste/patología , Vacuna contra la Peste/administración & dosificación , Vacuna contra la Peste/inmunología , Vacuna contra la Peste/farmacocinética , Proteínas Citotóxicas Formadoras de Poros/genética , Proteínas Citotóxicas Formadoras de Poros/inmunología , Proteínas Recombinantes , Reproducibilidad de los Resultados , Virulencia/genética , Yersinia pestis/patogenicidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...